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Two for T
T-cell activation requires costimulation in addition to the antigen-specific
signal. Recent results suggest that distinct costimulatory molecules
can specifically activate different types of T-cell response.
It is now well established that two signals are required to
activate T cells - one is the antigen-specific signal trans-
mitted by the T-cell receptor, the other a 'costimulatory'
signal that is provided by interactions between pairs of
molecules, one expressed on the surface of the T cell and
the other on the surface of the antigen-presenting cell.
Interaction between the molecules CD28 on the T cell
and B7-1 (CD80) or B7-2 (CD86) on the antigen-pre-
senting cell at least partly fulfills the requirement for a
second, costimulatory signal in T-cell activation. Recent
reports, however, indicate that these costimulatory mol-
ecules may play a hitherto unsuspected role in the differ-
ential activation of the two main classes of helper T cells
- known as Thl and Th2 cells - and may even inhibit
T-cell activation in some circumstances.
B7-CD28 costimulation and T-cell activation
T-cell receptor interaction with its natural ligand, a pep-
tide presented by a major histocompatibility complex
(MHC) molecule, is not sufficient to trigger full activation
of resting T cells. This was first suggested by Lafferty and
colleagues [1], who showed that foreign tissues depleted
of 'passenger leukocytes' were unable to induce a produc-
tive immune response. Furthermore, stimulation of T cells
with anti-T-cell receptor antibodies, mitogenic lectins in
the absence of viable antigen-presenting cells or fixed
antigen-presenting cells results in neither clonal expansion
nor interleukin-2 (IL-2) production [2,3]. This led to the
conclusion that a second, costimulatory signal provided by
antigen-presenting cell, together with the antigenic signal,
is required for the activation of resting T cells.
Numerous studies indicate that CD28, which is expres-
sed constitutively by both CD4+ (helper) and CD8+
(cytotoxic) T cells, can transmit costimulatory signals for
both types of T cell (see [3-5]). Following activation, T
cells express a second receptor, CTLA4, that is closely
related to CD28 [6]. Both receptors bind to the B7 fam-
ily of molecules, which includes at least two ligands,
B7-1 and B7-2 [4]. Expression of B7-1 or B7-2 confers
antigen-presenting-cell function on non-immunogenic
cells in vitro and in vivo. Conversely, blocking B7-CD28
interactions with monovalent 'Fab' fragments of anti-
CD28 antibodies, a soluble form of CTLA4 or B7-
specific antibodies effectively prevents the activation of
CD4+ T cells [4,7,8]. Moreover, most T-cell responses
are greatly reduced in CD28-deficient mice [9,10].
Most resting antigen-presenting cells do not express B7-1
or B7-2 in vivo [11]. Although the same mediators can
induce expression of both ligands, the kinetics of B7-2
induction are more rapid, and the level reached usually
higher, than is the case for B7-1. B7-2 seems to play the
more critical role in T-cell activation. Indeed, while bloc-
king B7-1 has only a marginal effect on T-cell activation,
blocking B7-2 almost completely abrogated antigen-
specific responses of CD4* T cells in vitro [4,7,8].
Different molecule, different functions?
Although most experiments have suggested that B7-1
and B7-2, and likewise CD28 and CTLA4, have identi-
cal functions, the existence of multiple receptor-ligand
pairs was puzzling. Evidence that T-cell costimulation is
more complex than originally thought has now come
from a set of surprising observations made by Kuchroo et
al. [12] and Lenschow et al. [13], who have examined the
specific effects of anti-B7-1 and anti-B7-2 antibodies on
the development of autoimmunity.
Kuchroo et al. [12] analyzed the effect of anti-B7 anti-
bodies on the development of experimental allergic
encephalomyelitis (EAE) in mice, following immuniza-
tion with proteolipoprotein (PLP). Injection of mice
with anti-B7-1 antibodies reduced the magnitude and
delayed the onset of disease, as compared with mice
immunized with PLP alone. By contrast, injection of
anti-B7-2 antibody exacerbated disease. Injection of both
anti-B7-1 and anti-B7-2 antibodies had only a marginal
effect in delaying the onset of EAE.
These different effects seem to be linked to a change in
the immune-response profile. Indeed, EAE, like several
autoimmune diseases, is primarily associated with the
generation of Thl-like CD4+ T cells, which secrete
mainly interferon-y (IFN-,y) and little IL-4. Treatment
with anti-B7-1 antibodies, which reduces disease, sub-
stantially reduces Thl-like responses to PLP, and appears
to be associated with an increased representation of PLP-
specific ThO or Th2 T cells. The effects of anti-B7 anti-
bodies in this experimental system seem, therefore, to be
associated with an alteration of the balance between
autoreactive encephalomyelitic Thl cells and regulatory
Th2 cells.
Contrasting results were obtained in a study of sponta-
neous autoimmune diabetes in NOD ('non-obese dia-
betic') mice. Lenschow et al. [13] first showed that
soluble CTLA4 prevented the development of insulin-
dependent diabetes mellitus (IDDM) and reduced insuli-
tis when administered at the time of its onset in NOD
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Fig. 1. The possible models to account for the recently observed [12,131 differential effects of the costimulatory molecules B7-1 and
B7-2 on the Thl and Th2 pathways in an immune response. See text for details.
mice. In this model system, administration of anti-B7-1
antibodies accelerated and exacerbated diabetes, whereas
anti-B7-2 antibodies completely eliminated spontaneous
IDDM but had little effect on insulitis. Surprisingly, a
combination of both antibodies exacerbated disease, sug-
gesting that the effect of the anti-B7-1 antibodies was
dominant. The immunological basis for the observed
effects of anti-B7-1 and anti-B7-2 antibody treatment
has not yet been elucidated. It is known, however, that
IDDM is exacerbated in transgenic NOD mice that con-
stitutively express B7-1 on their islets of Langerhans cells,
suggesting that B7-1 can participate in a productive
autoimmune response [14].
The development of EAE or spontaneous autoimmune
diabetes involves multiple different, and still poorly
understood, events, a complexity that might contribute to
the differences between the results obtained in the two
studies [12,13]. Three possible models to explain the
observed effects of anti-B7 antibodies on immune res-
ponses can be envisioned (Fig. 1). First, the two types of
B7 molecule might have different functions, so that their
differential engagement leads to a polarization of helper
T-cell responses (model 1) [12]. In this model, the inter-
actions of B7-1 and B7-2 with CD28/CTLA4 generate
different intracellular signals, causing the differentiation of
precursors along the Thl or Th2 pathway, respectively.
While B7-1 and B7-2 have very similar affinities for
CTLA4 and CD28, the off-rate of B7-2 is faster than that
of B7-1, which might influence signaling events [15].
Alternatively, B7-1 and B7-2 might bind different recep-
tors on T cells: B7-1 might preferentially bind to CTLA4,
and B7-2 to CD28, as CTLA4 more efficiently inhibits
the interaction of CD28 with B7-1 than with B7-2 [15].
The respective roles of CD28 and CTLA4 in providing
costimulatory signals for T-cell activation have not yet
been elucidated. Recent experiments suggest that CD28
might provide costimulatory signals for the activation of
most effector genes (including IL-2) and entry into the
cell cycle, whereas CTLA4 might provide negative signals
to T cells and therefore down-regulate on-going immune
responses [10,16,17]. Alternatively, Thl-type responses,
or IFN-'y production, may be less dependent on CD28/
B7 signals than Th2-type responses [18]. The analysis of
Thl and Th2 responses in B7- or CD28-deficient mice
will perhaps clarify these possibilities.
A second possibility involves the possible transduction of
signals by B7-1 and B7-2 to the antigen-presenting cell
(or T cell) on which they are expressed (model 2). In this
case, anti-B7 antibodies would either block these interac-
tions and therefore inhibit the signals, or, by crosslinking,
mimic the interactions and thereby deliver specific signals
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to the different cells that express B7-1 and B7-2.
Although no canonical signaling motif has so far been
identified in a B7 sequence, B7-1 and B7-2 differ quite
considerably in their transmembrane and cytoplasmic
domains [4]. Whether these differences are linked to dif-
ferent signaling pathways remains to be determined.
In NOD mice, treatment with non-crosslinking B7-1
Fab fragments reduces diabetes (J. Bluestone, personal
communication). In view of this, it seems more likely
that anti-B7-1 antibodies - which can crosslink their
target B7-1 molecules - have a potentiating effect on
diabetes because they stimulate B7-1 molecules to trans-
duce a signal to the antigen-presenting cells than because
they block the transduction by CD28 of a signal to the
T cells. Interestingly, antigen-presenting cells can pro-
duce IL-12, a potent regulator of immune responses that
favors Thl-type responses. B7 molecules may therefore
regulate immune responses by differentially regulating
IL-12 production by antigen-presenting cells. Studies of
B7-1- and/or B7-2-deficient mice should help to clarify
this issue.
Lastly, a negative-regulatory function of B7-1 is found in
transgenic mice that express B7-1 constitutively on their
B cells [19]. Antibody responses to T-cell-dependent
antigens were reduced in those mice but their T-cell
responses were normal, with no obvious alteration in the
balance between Thl- and Th2-type responses. Thus,
over-expression of B7-1 on B cells appears to interfere
with antigen-specific activation of B cells, either by inter-
fering with the delivery by T cells of essential signals to B
cells, or by interfering directly with B-cell activation.
The possibility that B7-1 regulates T cell-B cell interac-
tions, and thus B-cell responses, provides another inter-
pretation that might reconcile the findings of Kuchroo et
al. [12] and Lenschow et al. [13] (model 3). Indeed, in a
model where B7-1 regulates B-cell activation, blocking
B7-1 might enhance B-cell responses. While B cells may
protect against EAE [20,21], autoimmune diabetes may
depend on B-cell activation. B cells may play a critical
role in the diversification of immune responses: they
may trigger T-cell responses to additional, sub-dominant
intra- or inter-molecular determinants, a phenomenon
known as determinant spreading [22]. Interestingly, in a
rat model of EAE, induced by injection of PLP fragment
139-151, administration of anti-B7-1 antibodies follow-
ing recovery from the acute phase greatly exacerbates dis-
ease relapses. Moreover, T-cell responses to additional
PLP epitopes are also increased, suggesting that anti-B7-1
treatment enhances epitope spreading (S. Miller and
J. Bluestone, personal communication). Perhaps B cells
favor the differentiation of Th2 effector cells, a possibility
that remains to be tested.
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